A detailed history of Schonfeld Strategic Advisors LLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 1,882,600 shares of LXRX stock, worth $1.45 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,882,600
Previous 571,492 229.42%
Holding current value
$1.45 Million
Previous $960,000 207.81%
% of portfolio
0.02%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.51 - $2.39 $1.98 Million - $3.13 Million
1,311,108 Added 229.42%
1,882,600 $2.96 Million
Q2 2024

Aug 14, 2024

SELL
$1.54 - $2.28 $598,533 - $886,140
-388,658 Reduced 40.48%
571,492 $960,000
Q1 2024

May 15, 2024

BUY
$1.3 - $3.58 $1.25 Million - $3.44 Million
960,150 New
960,150 $2.3 Million
Q3 2023

Nov 14, 2023

SELL
$1.06 - $2.33 $24,884 - $54,699
-23,476 Reduced 4.76%
469,666 $511,000
Q2 2023

Aug 14, 2023

BUY
$2.15 - $3.49 $718,405 - $1.17 Million
334,142 Added 210.15%
493,142 $1.13 Million
Q1 2023

May 15, 2023

BUY
$1.99 - $2.68 $83,580 - $112,560
42,000 Added 35.9%
159,000 $386,000
Q4 2022

Feb 14, 2023

BUY
$1.8 - $2.56 $210,600 - $299,520
117,000 New
117,000 $223,000
Q1 2021

May 17, 2021

SELL
$3.45 - $9.09 $261,165 - $688,113
-75,700 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$1.05 - $3.67 $79,485 - $277,819
75,700 New
75,700 $259,000
Q4 2017

Feb 14, 2018

SELL
$8.77 - $12.28 $138,399 - $193,790
-15,781 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$12.17 - $16.3 $192,054 - $257,230
15,781
15,781 $194,000

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $145M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.